EarningsQ2 2026 Earnings Report
MX:HIMS Q2 2026 EPS Results
Actual EPS-$6.70
Consensus EPS-$0.90
Beat/MissMissed by -$5.79
One Year Ago EPS$3.08
MX:HIMS Q2 2026 Revenue Results
Actual Revenue$13.63B
Expected Revenue$12.65B
Beat/MissBeat by +$982.90M
YoY Revenue Growth+38.25%
Earnings Announcement Details
QuarterQ2 2026
Date08/10/2026
TimeAfter Close
Conference CallMonday, August 10, 2026
MX:HIMS Upcoming Earnings
Hims & Hers Health's next earnings date is estimated for November 9, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:HIMS Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and growth-oriented outlook: strong revenue and subscriber growth, raised guidance, meaningful international scale from the Eucalyptus acquisition, and promising AI-driven engagement and efficiency gains. These positives are tempered by margin compression from mix shift toward branded weight loss and international sales, a GAAP loss driven by one-time costs, short-term negative cash flow in the quarter, and regulatory/legal uncertainties (FTC action and dependence on FDA rulemaking for peptides). Management highlighted liquidity actions and expects AI investments to pay back within 12–18 months, signaling confidence in the path to improved profitability.Company Guidance
Strong Top-Line Growth
Revenue grew nearly 40% year-over-year to more than $753 million in Q2 2026, driven by expanded assortment, new geographies and subscriber additions.
Subscriber Expansion
Added more than 300,000 net new subscribers in Q2, bringing the global subscriber base to nearly 3 million, increasing scale and cross-sell opportunity.
Domestic and International Momentum
U.S. (domestic) revenue accelerated to $622 million, up ~16% year-over-year. International revenue increased over 17x year-over-year to $131 million, with Eucalyptus contributing approximately $40 million in Q2.
Adjusted EBITDA and Margin Improvement
Adjusted EBITDA was $60 million in Q2, representing an 8% adjusted EBITDA margin and a 1 percentage-point improvement quarter-over-quarter despite mix changes.
Raised Full-Year Guidance
Raised 2026 revenue outlook to $3.1–$3.3 billion (up ~32%–41% YoY) and expects 2026 adjusted EBITDA of $275–$325 million (implying ~9% margin at midpoint). Q3 revenue guide is $880–$900 million (+47%–50% YoY).
AI-Driven Engagement and Efficiency Gains
AI pilot for Hers weight loss showed customers sending 3x as many messages, AI answering ~80% of questions, and a near 50% reduction in nonclinical tasks handled by support—early signals of higher engagement and lower cost to serve.
Product & Specialty Expansion
Testosterone specialty is scaling quickly and is expected to become the sixth U.S. specialty to reach a $100 million annual run rate; Hers is on track for north of $1 billion in revenue this year. Company plans oral and injectable TRT launches and clinical expansion into peptides and longevity offerings.
Balance Sheet and Liquidity Actions
Ended Q2 with more than $840 million of cash and short-term investments after the Eucalyptus upfront payment; established a $400 million receivables facility and completed a convertible debt offering of over $400 million to support growth and working capital needs.
MX:HIMS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed